The National Cancer Institute: cancer drug discovery and development program.
The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description of the ongoing efforts at the National Cancer Institute (NCI) is intended to provide insight into those complex processes necessary to accomplish this mission. An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. The tremendous potential advantages and challenges associated with the use of a molecular approach to cancer drug design are discussed. Despite the differences of opinion that may exist regarding the optimal strategies for accomplishing the mission, there is no disagreement regarding the importance of the effort to find effective new therapies for cancer patients.
Grever
M R
MR
Director, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Schepartz
S A
SA
Chabner
B A
BA
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D015195:Drug Design; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy*; D014481:United States
D000970:Antineoplastic Agents; D015507:Drugs, Investigational